Sanjiv S. Agarwala
Temple University Hospital(US)Health Professionals Advancing LGBT Equality(US)Temple University(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses
Most-Cited Works
- → Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma(2015)2,746 cited
- → Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma(2015)2,541 cited
- → Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer(2007)1,696 cited
- → Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial(2015)1,554 cited
- → Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial(2016)972 cited
- → High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801